title: Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe Asthma.
authors.affiliation: 1 University of Leicester Leicester, United Kingdom.
authors.forename: Christopher E
authors.initials: CE
authors.lastname: Brightling
authors.affiliation: 2 AstraZeneca Mölndal, Sweden.
authors.forename: Lars H
authors.initials: LH
authors.lastname: Nordenmark
authors.affiliation: 3 MedImmune Cambridge, United Kingdom.
authors.forename: Meena
authors.initials: M
authors.lastname: Jain
authors.affiliation: 4 AstraZeneca Cambridge, United Kingdom.
authors.forename: Edward
authors.initials: E
authors.lastname: Piper
authors.affiliation: 5 MedImmune Gaithersburg, Maryland and.
authors.forename: Dewei
authors.initials: D
authors.lastname: She
authors.affiliation: 4 AstraZeneca Cambridge, United Kingdom.
authors.forename: Martin
authors.initials: M
authors.lastname: Braddock
authors.affiliation: 6 AstraZeneca Gaithersburg, Maryland.
authors.forename: Gene
authors.initials: G
authors.lastname: Colice
authors.affiliation: 2 AstraZeneca Mölndal, Sweden.
authors.forename: Göran
authors.initials: G
authors.lastname: Tornling
mesh_terms: D056151:Airway Remodeling / Q000187:drug effects*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D018793:Interleukin-13 / Q000037:antagonists & inhibitors*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D018793:Interleukin-13; C574065:tralokinumab